|
|
Volumn 31, Issue 3, 2008, Pages 185-198
|
|
The US FDA 'black box' warning for topical calcineurin inhibitors: An ongoing controversy
|
|
Author keywords
Atopic dermatitis; Calcineurin inhibitors, adverse reactions; Labelling; Pharmacovigilance; Pimecrolimus, adverse reactions; Tacrolimus, adverse reactions; Tacrolimus, therapeutic use
|
|
Indexed keywords
ALPHA TOCOPHEROL;
ASCOMYCIN;
CALCINEURIN INHIBITOR;
CLOBETASOL;
CORTICOSTEROID;
CYCLOSPORIN;
DAPSONE;
DEXAMETHASONE;
ETRETIN;
IMMUNOSUPPRESSIVE AGENT;
MOMETASONE FUROATE;
PIMECROLIMUS;
TACROLIMUS;
TRIAMCINOLONE ACETONIDE;
ADRENAL CORTEX FUNCTION;
APPLICATION SITE BURNING;
ATOPIC DERMATITIS;
B CELL LYMPHOMA;
BALANOPOSTHITIS;
BASAL CELL CARCINOMA;
CHRONIC INFLAMMATION;
CLINICAL TRIAL;
CREAM;
DERMATITIS;
DRUG APPROVAL;
DRUG DOSE INCREASE;
DRUG EFFICACY;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG WITHDRAWAL;
FOOD AND DRUG ADMINISTRATION;
GROWTH RETARDATION;
HODGKIN DISEASE;
HUMAN;
LICHEN PLANUS;
LYMPHOMA;
MYCOSIS FUNGOIDES;
NONHODGKIN LYMPHOMA;
NONHUMAN;
OINTMENT;
POSTMARKETING SURVEILLANCE;
PRIORITY JOURNAL;
PRURITUS;
RECURRENT DISEASE;
REVIEW;
RISK BENEFIT ANALYSIS;
ROSACEA;
SEZARY SYNDROME;
SIDE EFFECT;
SKIN ATROPHY;
SKIN CANCER;
SQUAMOUS CELL CARCINOMA;
TACHYPHYLAXIS;
|
|
EID: 39749187188
PISSN: 01145916
EISSN: None
Source Type: Journal
DOI: 10.2165/00002018-200831030-00001 Document Type: Review |
|
Times cited : (95)
|
|
References (101)
|
